Other researchers using doxofylline in the treatment of COPD have found that it can increase the release of IL‐10 and exhibit an anti‐inflammatory and immunomodulatory effect, inhibit the release of inflammatory mediators by mast cells and the oxygen reactive of neutrophils,24 inhibit the translocation of proinflammatory transcription factor nuclear factor B (NF‐κB) into the nucleus and reduce the expression of inflammatory genes,25 and promote the apoptosis of neutrophils in vitro by reducing the anti‐apoptotic protein Bcl‐2.26 This evidence concerns the gene BCL2 and chronic obstructive pulmonary disease.